|PYC -- Australia Stock|| |
AUD 0.025 0.003 10.71%
Chief Scientific Officer
Dr. Paul Michael Watt is NonExecutive Director of Phylogica Ltd. He is a graduate from The University of Western Australia. He completed his doctorate in Molecular Biology at Oxford University before taking up postdoctoral appointments in yeast genetics at Harvard and Oxford Universities. He discovered three novel genes, including the yeast homologue of the human Bloom and Werner syndrome genes involved in cancer susceptibility. He is an Honorary Research fellow at the Telethon Institute for Child Health Research and an Adjunct Professor at the school of Paediatrics and Child Health of the University for Western Australia. Dr. Watt has published more than 45 peer reviewed scientific papers. Dr. Watt has more than 12 years experience in commercializing intellectual property and is the primary inventor on 20 patents. He founded InfaMed Ltd., now owned by Avita Medical Ltd.
Age: 47 Executive Since 2016
61 8 9489 7777 http://www.phylogica.com.au
The company has return on total asset (ROA)
of (85.88) %
which means that it has lost $85.88 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (91.1) %
meaning that it generated substantial loss on money invested by shareholders.
Phylogica Limited provides drug discovery research and development services utilizing Phylomer peptide libraries and proprietary screening capabilities in Australia. It has approximately 12 patent families comprising multiple grantedallowed patents in the United States and Australia, which cover methods of making the Phylomer libraries methods of screening them and composition-of-matter claims for Phylomer libraries and individual Phylomer peptides discovered for therapeutic and diagnostic applications. Phylogica operates under Biotechnology classification in Australia and traded on Australian Securities Exchange.Phylogica Limited (PYC) is traded on Australian Securities Exchange in Australia. It is located in Telethon Kids Institute and employs 5 people.
Phylogica Limited Leadership Team
|Douglas Wilson, Chairman, Ph.D|
|Bernard Hockings, Director, Ph.D|
|Paul Watt, Executive|
|Sahm Nasseri, Director, MBA|
|Kevin Hart, CFO|
|Graeme Boden, CFO, CPA|
|Rudi Michelson, Executive|
|Alan Tribe, Executive|
|Rick Kendall, Director, Ph.D|
|Stephanie Unwin, Director|
|Robert Hayes, Director, Ph.D|
|Bruce McHarrie, Director|
|Natasha Forde, Executive|
|Richard Hopkins, CEO|
|Michael Williams, Director|
|Jeremy CurnockCook, Director|
|Rohan Hockings, Director|
Stock Performance Indicators
Most of Macroaxis users are at this time bullish on Phylogica Limited. What is your perspective on investing in Phylogica Limited? Are you bullish or bearish?
Additionally take a look at Your Equity Center
. Please also try Companies Directory
module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.